The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
|Articles|September 3, 2013
Mechanism of Action: Antibody-Drug Conjugates
Despite recent oncology breakthroughs, conventional anticancer treatments may have limitations. Decades of research are resulting in the capacity to create a new generation of antibody drug conjugates.
Advertisement
Advertisement
Related to this article
More than 76% of US counties have no TNBC trial, and only 9.8% of rural counties have one vs 47% of metropolitan counties, a new analysis finds.
Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.
Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.
Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.
Early multidisciplinary survivorship care during radiotherapy boosts adherence and improves disease-free survival in head and neck cancer, with lower recurrence risk.
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
4
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
5